A new single-dose vaccine, Vimkunya, developed for the chikungunya virus has shown efficacy in a large clinical trial involving over 3,200 adolescents and adults. The vaccine demonstrated rapid and durable immune responses, well-tolerated overall, and is a potential option for individuals aged 12 years and older. The study also confirmed consistent performance across all three production lots and stronger responses in participants with preexisting immunity to the virus.

Source: The Lancet